• Home
  • Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Author List
Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ
Publication
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1437272
Publication Year
2004
PubMed ID
15173098
Publication Title
Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004 Jun 01; 10(11):3885-96.